NEOPHARM ANNOUNCES JAPANESE LICENSING AGREEMENT FOR IL13-PE38QQR WITH NIPPON KAYAKU

NeoPharm has announced that Nippon Kayaku has signed an exclusive license agreement with NeoPharm for the Japanese development rights for IL13-PE38QQR, generically known as cintredekin besudotox, which is NeoPharm's lead drug candidate for the treatment of glioblastoma multiforme (GBM). According to terms of the agreement, NeoPharm received an initial up-front license fee of $2 million. Nippon Kayaku is responsible for all development costs in Japan.

Yahoo News (http://biz.yahoo.com/bw/050104/45423_1.html)